FOXP3 and endometrial cancer: Although further verification is necessary for the exact prognostic role of CD25+FOXP3+CD45RA− Treg cells in endometrial cancer, these lines of evidence together with our current findings suggest that the therapeutic manipulation of CD25+FOXP3+CD45RA− effector Treg cells by antibodies, vaccines, or small molecules may promote tumor angiogenesis and chemosensitivity leading to improvement of patient prognosis in endometrial cancer.